SELLAS Life Sciences Group, Inc. Increase (Decrease) in Assets Held-for-sale
SELLAS Life Sciences Group, Inc. (SLS) reported Increase (Decrease) in Assets Held-for-sale of -$683.00 thousand for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAssetsHeldForSale · last filed 2017-11-09
- SELLAS Life Sciences Group, Inc. increase (decrease) in assets held-for-sale for the quarter ending 2017-09-30 was $2.57M.
- SELLAS Life Sciences Group, Inc. increase (decrease) in assets held-for-sale for the quarter ending 2017-06-30 was $1.18M, a 56.56% increase year-over-year.
- SELLAS Life Sciences Group, Inc. increase (decrease) in assets held-for-sale for the quarter ending 2017-03-31 was -$4.43M, a 5376.19% decline year-over-year.
- SELLAS Life Sciences Group, Inc. increase (decrease) in assets held-for-sale for the quarter ending 2016-12-31 was -$1.05M.
- SELLAS Life Sciences Group, Inc. increase (decrease) in assets held-for-sale for fiscal 2016 was -$763.00K.
- SELLAS Life Sciences Group, Inc. increase (decrease) in assets held-for-sale for fiscal 2015 was -$2.97M.
- SELLAS Life Sciences Group, Inc. increase (decrease) in assets held-for-sale for fiscal 2014 was -$2.49M, a 924.50% decline from fiscal 2013.
- SELLAS Life Sciences Group, Inc. increase (decrease) in assets held-for-sale for fiscal 2013 was $302.00K.
| Period end | Increase (Decrease) in Assets Held-for-sale 3 month | Increase (Decrease) in Assets Held-for-sale 6 month | Increase (Decrease) in Assets Held-for-sale 9 month | Increase (Decrease) in Assets Held-for-sale 12 month |
|---|---|---|---|---|
| 2017-09-30 | $2.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $3.75M derived: sum of 2 quarters · filed 2017-11-09 | -$683.00K 10-Q · filed 2017-11-09 | -$1.73M derived: sum of 4 quarters · filed 2017-11-09 |
| 2017-06-30 | $1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | -$3.25M 10-Q · filed 2017-08-14 | -$4.30M derived: sum of 3 quarters · filed 2017-08-14 | -$4.85M derived: sum of 4 quarters · filed 2017-11-09 |
| 2017-03-31 | -$4.43M 10-Q · filed 2017-05-10 | -$5.48M derived: sum of 2 quarters · filed 2017-05-10 | -$6.03M derived: sum of 3 quarters · filed 2017-11-09 | -$5.28M derived: sum of 4 quarters · filed 2017-11-09 |
| 2016-12-31 | -$1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | -$1.60M derived: sum of 2 quarters · filed 2017-11-09 | -$847.00K derived: sum of 3 quarters · filed 2017-11-09 | -$763.00K 10-K · filed 2017-03-15 |
| 2016-09-30 | -$551.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $204.00K derived: sum of 2 quarters · filed 2017-11-09 | $288.00K 10-Q · filed 2017-11-09 | $276.00K derived: sum of 4 quarters · filed 2017-11-09 |
| 2016-06-30 | $755.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $839.00K 10-Q · filed 2017-08-14 | $827.00K derived: sum of 3 quarters · filed 2017-08-14 | -$1.69M derived: sum of 4 quarters · filed 2017-08-14 |
| 2016-03-31 | $84.00K 10-Q · filed 2017-05-10 | $72.00K derived: sum of 2 quarters · filed 2017-05-10 | -$2.45M derived: sum of 3 quarters · filed 2017-05-10 | -$1.71M derived: sum of 4 quarters · filed 2017-05-10 |
| 2015-12-31 | -$12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | -$2.53M derived: sum of 2 quarters · filed 2017-03-15 | -$1.80M derived: sum of 3 quarters · filed 2017-03-15 | -$2.97M 10-K · filed 2017-03-15 |
| 2015-09-30 | -$2.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$1.78M derived: sum of 2 quarters · filed 2016-11-09 | -$2.96M 10-Q · filed 2016-11-09 | -$2.21M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-06-30 | $735.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$437.00K 10-Q · filed 2016-08-09 | $314.00K derived: sum of 3 quarters · filed 2017-03-15 | |
| 2015-03-31 | -$1.17M 10-Q · filed 2016-05-10 | -$421.00K derived: sum of 2 quarters · filed 2017-03-15 | ||
| 2014-12-31 | $751.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | -$2.49M 10-K · filed 2017-03-15 | ||
| 2014-09-30 | -$3.24M 10-Q · filed 2015-11-09 | |||
| 2013-12-31 | $302.00K 10-K/A · filed 2016-04-15 | |||
| 2012-12-31 | $0.00 8-K · filed 2015-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |